Skip to content

Return to the Full Article View You can republish this story for free. Click the "Copy HTML" button below. Questions? Get more details.

Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?

Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces — as well as the state of play on Capitol Hill and in the states concerning efforts to lower prescription drug costs.

Plus, for “extra credit,” the panelists recommend their favorite health stories of the week they think you should read, too.

Mary Agnes Carey: Kaiser Health News’ “End-Of-Life Advice: More Than 500,000 Chat On Medicare’s Dime,” by JoNel Aleccia.

Margot Sanger-Katz: Bloomberg’s “Failing or Doing Fine? How Obamacare’s Marketplaces Are Shaping Up for 2018,” by Hannah Recht.

Sarah Karlin-Smith: The New York Times’ “A Cancer Conundrum: Too Many Drug Trials, Too Few Patients,” by Gina Kolata.

Julie Appleby: The Wall Street Journal’s “The New Innovator’s Dilemma: When Customers Won’t Pay for Better,” by Denise Roland.

To hear all our podcasts, click here.

And subscribe to What the Health? on iTunesStitcher or Google Play.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

Some elements may be removed from this article due to republishing restrictions. If you have questions about available photos or other content, please contact khnweb@kff.org.